512 related articles for article (PubMed ID: 24756798)
1. Ruxolitinib.
Becker H; Engelhardt M; von Bubnoff N; Wäsch R
Recent Results Cancer Res; 2014; 201():249-57. PubMed ID: 24756798
[TBL] [Abstract][Full Text] [Related]
2. Ruxolitinib.
Ajayi S; Becker H; Reinhardt H; Engelhardt M; Zeiser R; von Bubnoff N; Wäsch R
Recent Results Cancer Res; 2018; 212():119-132. PubMed ID: 30069628
[TBL] [Abstract][Full Text] [Related]
3. Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.
Vaddi K; Sarlis NJ; Gupta V
Expert Opin Pharmacother; 2012 Nov; 13(16):2397-407. PubMed ID: 23051187
[TBL] [Abstract][Full Text] [Related]
4. Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.
Ostojic A; Vrhovac R; Verstovsek S
Future Oncol; 2011 Sep; 7(9):1035-43. PubMed ID: 21919691
[TBL] [Abstract][Full Text] [Related]
5. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
[TBL] [Abstract][Full Text] [Related]
6. Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis.
Martí-Carvajal AJ; Anand V; Solà I
Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD010298. PubMed ID: 25860512
[TBL] [Abstract][Full Text] [Related]
7. Practical management of myelofibrosis with ruxolitinib.
Ho PJ; Marlton P; Tam C; Stevenson W; Ritchie D; Bird R; Dunlop LC; Durrant S; Ross DM
Intern Med J; 2015 Dec; 45(12):1221-30. PubMed ID: 26648193
[TBL] [Abstract][Full Text] [Related]
8. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger M; Miller C; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner E; Lyons RM; Paquette R; Raza A; Vaddi K; Erickson-Viitanen S; Koumenis IL; Sun W; Sandor V; Kantarjian HM
N Engl J Med; 2012 Mar; 366(9):799-807. PubMed ID: 22375971
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis.
Jung CW; Shih LY; Xiao Z; Jie J; Hou HA; Du X; Wang MC; Park S; Eom KS; Oritani K; Okamoto S; Tauchi T; Kim JS; Zhou D; Saito S; Li J; Handa H; Jianyong L; Ohishi K; Hou M; Depei W; Takenaka K; Liu T; Hu Y; Amagasaki T; Ito K; Gopalakrishna P; Akashi K
Leuk Lymphoma; 2015 Jul; 56(7):2067-74. PubMed ID: 25315076
[TBL] [Abstract][Full Text] [Related]
10. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
Al-Ali HK; Griesshammer M; Foltz L; Palumbo GA; Martino B; Palandri F; Liberati AM; le Coutre P; García-Hernández C; Zaritskey A; Tavares R; Gupta V; Raanani P; Giraldo P; Hänel M; Damiani D; Sacha T; Bouard C; Paley C; Tiwari R; Mannelli F; Vannucchi AM
Br J Haematol; 2020 Jun; 189(5):888-903. PubMed ID: 32017044
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
Verstovsek S; Kantarjian H; Mesa RA; Pardanani AD; Cortes-Franco J; Thomas DA; Estrov Z; Fridman JS; Bradley EC; Erickson-Viitanen S; Vaddi K; Levy R; Tefferi A
N Engl J Med; 2010 Sep; 363(12):1117-27. PubMed ID: 20843246
[TBL] [Abstract][Full Text] [Related]
12. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
[TBL] [Abstract][Full Text] [Related]
13. JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease.
Evrot E; Ebel N; Romanet V; Roelli C; Andraos R; Qian Z; Dölemeyer A; Dammassa E; Sterker D; Cozens R; Hofmann F; Murakami M; Baffert F; Radimerski T
Clin Cancer Res; 2013 Nov; 19(22):6230-41. PubMed ID: 24081976
[TBL] [Abstract][Full Text] [Related]
14. Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib.
Wilkins BS; Radia D; Woodley C; Farhi SE; Keohane C; Harrison CN
Haematologica; 2013 Dec; 98(12):1872-6. PubMed ID: 24056820
[TBL] [Abstract][Full Text] [Related]
15. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
[TBL] [Abstract][Full Text] [Related]
16. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
Bryan JC; Verstovsek S
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
[TBL] [Abstract][Full Text] [Related]
17. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
Verstovsek S
Postgrad Med; 2013 Jan; 125(1):128-35. PubMed ID: 23391678
[TBL] [Abstract][Full Text] [Related]
18. Ruxolitinib for myelofibrosis.
Haznedaroglu IC
N Engl J Med; 2012 May; 366(21):2032; author reply 2032-5. PubMed ID: 22621635
[No Abstract] [Full Text] [Related]
19. Ruxolitinib for myelofibrosis.
Koschmieder S; Koppelle A; Seifert H
N Engl J Med; 2012 May; 366(21):2031-2; author reply 2032-4. PubMed ID: 22621634
[No Abstract] [Full Text] [Related]
20. Ruxolitinib for myelofibrosis.
Diamantidis MD
N Engl J Med; 2012 May; 366(21):2031; author reply 2032-4. PubMed ID: 22621633
[No Abstract] [Full Text] [Related]
[Next] [New Search]
